Precigen

Historical price data

Precigen is a commercial-stage biopharmaceutical company focused on developing precision gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases. The company achieved a critical inflection point with the FDA approval of PAPZIMEOS in August 2025 for recurrent respiratory papillomatosis (RRP). Its strategy is built on two proprietary technology platforms—AdenoVerse® for viral vector gene delivery and UltraCAR-T® for next-generation cell therapy—designed to overcome key limitations in the field and create a sustainable pipeline of advanced therapeutics.

Precigen's core technologies are the AdenoVerse® platform, a proprietary gorilla adenovector system for in vivo gene delivery with low seroprevalence and repeat-dosing capability, and the UltraCAR-T® platform, a non-viral, rapid-manufacturing CAR-T cell therapy system designed for enhanced persistence and solid tumor activity.